This list of included articles is based on preliminary data-extraction for the CAG 2022 Conference.
Adhiyaman, V., & Arshad, S. (2014). Cannabis for intractable nausea after bilateral cerebellar stroke. Journal of the American Geriatrics Society, 62(6), 1199. https://doi.org/10.1111/jgs.12856
Ahmed, A. I., van den Elsen, G. A., Colbers, A., Kramers, C., Burger, D. M., van der Marck, M. A., & Olde Rikkert, M. G. (2015). Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology, 232(14), 2587–2595. https://doi.org/10.1007/s00213-015-3889-y
Cohen, L. M., Ash, E., Outen, J. D., Vandrey, R., Amjad, H., Agronin, M., Burhanullah, M. H., Walsh, P., Wilkins, J. M., Leoutsakos, J. M., Nowrangi, M. A., Harper, D., Rosenberg, P. B., & Forester, B. P. (2021). Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s dementia (THC-AD). International psychogeriatrics, 1–6. Advance online publication. https://doi.org/10.1017/S1041610221001150
Chagas, M. H., Eckeli, A. L., Zuardi, A. W., Pena-Pereira, M. A., Sobreira-Neto, M. A., Sobreira, E. T., Camilo, M. R., Bergamaschi, M. M., Schenck, C. H., Hallak, J. E., Tumas, V., & Crippa, J. A. (2014). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. Journal of clinical pharmacy and therapeutics, 39(5), 564–566. https://doi.org/10.1111/jcpt.12179
Holden, S. K., Domen, C. H., Sillau, S., Liu, Y., & Leehey, M. A. (2022). Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson’s Disease. Movement disorders clinical practice, 9(3), 340–350. https://doi.org/10.1002/mdc3.13414
Passmore M. J. (2008). The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. International journal of geriatric psychiatry, 23(1), 116–117. https://doi.org/10.1002/gps.1828
Ruthirakuhan, M., Herrmann, N., Andreazza, A.C., Verhoeff, N.P.L., Gallagher, D., Black, S.E. and Lanctot, K.L. (2020), Biomarkers of agitation in moderate-to-severe Alzheimer’s disease patients enrolled in an RCT with nabilone. Alzheimer’s Dement., 16: e042269. https://doi.org/10.1002/alz.042269
Tumati, S., Lanctôt, K.L., Wang, R. et al. Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects. Drugs Aging 39, 153–163 (2022). https://doi.org/10.1007/s40266-021-00913-y
van den Elsen, G., Ahmed, A., Verkes, R. J., Feuth, T., van der Marck, M. A., & Olde Rikkert, M. (2015). Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 23(12), 1214–1224. https://doi.org/10.1016/j.jagp.2015.07.011
Volicer, L., Stelly, M., Morris, J., McLaughlin, J., & Volicer, B. J. (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. International journal of geriatric psychiatry, 12(9), 913–919.
Walther, S., Mahlberg, R., Eichmann, U., & Kunz, D. (2006). Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology, 185(4), 524–528. https://doi.org/10.1007/s00213-006-0343-1